493 related articles for article (PubMed ID: 35273597)
1. CD8
Zhang M; Ma J; Guo Q; Ding S; Wang Y; Pu H
Front Immunol; 2022; 13():806877. PubMed ID: 35273597
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
3. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
4. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
Front Immunol; 2022; 13():749241. PubMed ID: 35529878
[TBL] [Abstract][Full Text] [Related]
5. Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing.
Song P; Li W; Guo L; Ying J; Gao S; He J
Front Immunol; 2022; 13():850745. PubMed ID: 35757748
[TBL] [Abstract][Full Text] [Related]
6. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
7. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma.
Luo Y; Zhang S; Xie H; Su Q; He S; Lei Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):51-61. PubMed ID: 38279482
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
[TBL] [Abstract][Full Text] [Related]
9. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
[TBL] [Abstract][Full Text] [Related]
10. Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
Li X; Zhang D; Guo P; Ma S; Gao S; Li S; Yuan Y
Aging (Albany NY); 2024 Apr; 16(7):6290-6313. PubMed ID: 38575204
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
[TBL] [Abstract][Full Text] [Related]
12. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q
Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077
[TBL] [Abstract][Full Text] [Related]
13. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
16. Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes.
Duan G; Huang C; Zhao J; Zhang Y; Zhao W; Dai H
Sci Rep; 2023 Nov; 13(1):20930. PubMed ID: 38017020
[TBL] [Abstract][Full Text] [Related]
17. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.
Fan T; Liu Y; Liu H; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
Cancer Immunol Immunother; 2021 Dec; 70(12):3651-3667. PubMed ID: 33977344
[TBL] [Abstract][Full Text] [Related]
19. Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma.
Han L; Shi H; Luo Y; Sun W; Li S; Zhang N; Jiang X; Gong Y; Xie C
Cancer Med; 2020 Dec; 9(24):9581-9594. PubMed ID: 33098370
[TBL] [Abstract][Full Text] [Related]
20. A robust CD8
Feng J; Xu L; Zhang S; Geng L; Zhang T; Yu Y; Yuan R; He Y; Nan Z; Lin M; Guo H
Front Immunol; 2022; 13():993187. PubMed ID: 36119068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]